Fan W, et al. - Researchers conducted this investigation to quantify the prevalence of hypertriglyceridemia (HTG) in US adults with diabetes currently treated compared with not treated with statins and to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk. They compared the prevalence of borderline HTG (TG 150–199 mg/dL) and HTG (TG ≥ 200 mg/dL) by statin use and LDL-C levels among 1,448 US adults aged 20 years and over with diabetes (projected to 24.4 million) in the 2007–2014 National Health and Nutrition Examination Survey. Borderline HTG and HTG prevalence were 20.0% and 19.5% respectively in statin users and 20.1% and 25.3% respectively in nonstatin users. Borderline HTG prevalence was 16.8% even among statin users with LDL-C < 70 mg/dL, and HTG prevalence was 16.7%. About 77.5% of those with HTG had an estimated 10-year ASCVD risk of ≥ 7.5%, with nearly 40% of statin users having ASCVD risk ≥ 20%. Residual HTG exists in US adults with diabetes over one-fifth (∼5.5 million), including those on statin therapy and well-controlled LDL-C. More than three-quarters of adults with diabetes with HTG are at medium to high risk of ASCVD for 10 years. To encourage lifestyle and pharmacological means for addressing residual HTG, greater efforts are needed.